Skip to main content
SupplementScience

Huperzine A Research & Evidence

This content is for informational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any supplement. Full disclaimer

Evidence Level

Moderate

Huperzine A has been extensively studied in China, with moderate-quality clinical evidence supporting its cognitive benefits. A 2014 meta-analysis of Chinese RCTs found significant improvements in MMSE scores for Alzheimer's patients. Xu et al. (1999) demonstrated memory benefits in elderly subjects with age-related memory complaints. Its dual mechanism — AChE inhibition plus NMDA antagonism — provides a broader neuroprotective profile than single-mechanism compounds. However, most high-quality trials are from Chinese literature, and large Western multicenter trials are lacking.

Evidence by Condition

ConditionStudied DoseEvidence
Memory enhancement50-200mcg twice dailyModerate
Neuroprotection200mcg twice dailyEmerging
Study/learning aid50-100mcg twice dailyEmerging
Full Huperzine A Guide

References

  1. (). Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Acta Pharmacologica Sinica.
  2. (). Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PLoS ONE. DOI
  3. (). Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students. Acta Pharmacologica Sinica.